Immunotherapeutic advances in glioma management: The rise of vaccine‐based approaches
Authors: Andrew Awuah Wireko , Shah Muhammad Hamza , Tan Joecelyn Kirani , Ranganathan Sruthi , Sanker Vivek , Darko Kwadwo , Tenkorang Pearl Ohenewaa , Adageba Bryan Badayelba , Ahluwalia Arjun , Shet Vallabh , Aderinto Nicholas , Kundu Mrinmoy , Abdul‐Rahman Toufik , Atallah Oday 
Published: August 2024

AbstractBackgroundGliomas, particularly glioblastoma multiforme (GBM), are highly aggressive brain tumors that present significant challenges in oncology due to their rapid progression and resistance to conventional therapies. Despite advancements in treatment, the prognosis for patients with GBM remains poor, necessitating the exploration of novel therapeutic approaches. One such emerging strategy is the development of glioma vaccines, which aim to stimulate the immune system to target and destroy tumor cells.AimsThis review aims to provide a comprehensive evaluation of the current landscape of glioma vaccine development, analyzing the types of vaccines under investigation, the outcomes of clinical trials, and the challenges and opportunities associated with their implementation. The goal is to highlight the potential of glioma vaccines in advancing more effective and personalized treatments for glioma patients.Materials and MethodsThis narrative review systematically assessed the role of glioma vaccines by including full‐text articles published between 2000 and 2024 in English. Databases such as PubMed/MEDLINE, EMBASE, the Cochrane Library, and Scopus were searched using key terms like “glioma,” “brain tumor,” “glioblastoma,” “vaccine,” and “immunotherapy.” The review incorporated both pre‐clinical and clinical studies, including descriptive studies, animal‐model studies, cohort studies, and observational studies. Exclusion criteria were applied to omit abstracts, case reports, posters, and non‐peer‐reviewed studies, ensuring the inclusion of high‐quality evidence.ResultsClinical trials investigating various glioma vaccines, including peptide‐based, DNA/RNA‐based, whole‐cell, and dendritic‐cell vaccines, have shown promising results. These vaccines demonstrated potential in extending survival rates and managing adverse events in glioma patients. However, significant challenges remain, such as therapeutic resistance due to tumor heterogeneity and immune evasion mechanisms. Moreover, the lack of standardized guidelines for evaluating vaccine responses and issues related to ethical considerations, regulatory hurdles, and vaccine acceptance among patients further complicate the implementation of glioma vaccines.DiscussionAddressing the challenges associated with glioma vaccines involves exploring combination therapies, targeted approaches, and personalized medicine. Combining vaccines with traditional therapies like radiotherapy or chemotherapy may enhance efficacy by boosting the immune system’s ability to fight tumor cells. Personalized vaccines tailored to individual patient profiles present an opportunity for improved outcomes. Furthermore, global collaboration and equitable distribution are critical for ensuring access to glioma vaccines, especially in low‐ and middle‐income countries with limited healthcare resourcesConclusionGlioma vaccines represent a promising avenue in the fight against gliomas, offering hope for improving patient outcomes in a disease that is notoriously difficult to treat. Despite the challenges, continued research and the development of innovative strategies, including combination therapies and personalized approaches, are essential for overcoming current barriers and transforming the treatment landscape for glioma patients.